Metro
Court adjourns Anthony Joshua driver’s trial to March 17
The Sagamu magistrate court has adjourned the trial of Adeniyi Kayode, driver in the Lexus crash involving former world heavyweight champion Anthony Joshua, to March 17, 2026.
During Wednesday’s hearing, R.D. Kadiri, counsel representing the Department of Public Prosecution (DPP), said prosecutors required more time to gather additional evidence and summon witnesses.
Kadiri added that the case file had been forwarded to the Ogun State DPP by the police for further legal advice.
Defence counsel, Olalekan Abiodun, opposed the adjournment, arguing that three witnesses were present and the trial should commence.
Magistrate Olufunilayo Somefun ruled the case should be postponed to allow the prosecutor to complete legal procedures.
This newspaper reports that the crash occurred on December 29, 2025, near Sinoma, Sagamu, as Joshua and three associates were travelling from Lagos.
Joshua survived with minor injuries, while his personal trainer, Kevin Latif Ayodele, and long-time strength and conditioning coach, Sina Ghami, died in the collision.
Joshua was discharged from Lagoon Hospital, Ikoyi, on December 31, 2025, after treatment.
The driver, Kayode, is facing charges of reckless driving.
Magistrate Somefun ordered that the case file be duplicated and forwarded to the Ogun State attorney-general to complete prosecution preparations before trial.
-
Politics15 hours ago2027 Elections Under Global Watch – Emeka Anyaoku Warns INEC
-
News15 hours agoNigerian army kills 45 bandits in renewed militant clash in Katsina
-
Politics15 hours agoAdelabu faces ministerial exit as governorship ambition thickens
-
News15 hours agoDeath Toll In Benue LGA Attacks Rises To 24
-
News15 hours agoTroops rescue 19 kidnapped victims in Abuja, recover weapons
-
Politics16 hours agoElectoral Act: Outrage over removal of certificate forgery as ground for election petition
-
Sports15 hours agoArsenal survive Mansfield scare to reach FA Cup quarter-finals
-
Business15 hours agoHow tax waiver, FX stability pushed pharma firms’ profits to decade-high
